The subject has a history of allergy or intolerance to flucytosine
No known allergy to aspirin
Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab
Known allergy to boron or excipients in the formulation
Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)
Patient has history of allergy to any oily drug products
Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the study agents
Known allergy to enadenotucirev, nivolumab or their excipients
Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301
Prior allergy or adverse reaction to methotrexate
No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)
Known allergy to egg products or soy bean oil
Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient
A history of a severe contrast allergy (i.e. anaphylaxis) not controlled with premedication
Known allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extract
Patients with a latex allergy
Known in tolerance and allergy to cytarabine.
Previous known allergy or intolerance to pembrolizumab or any of its excipients
Previous exposure or known allergy to Imprime PGG or any of its excipients
Known allergy to grapes or grape seed
Have known allergy to ovalbumin or other egg products
Allergy to benzamide or inactive components of entinostat.
Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination
Bovine product allergy
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to shellfish
Milk allergy
Known history of contrast allergy that cannot be medically managed
EXCLUSION - TREATMENT: Known allergy to VZV vaccine
Known allergy to HCQ
Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)
Patients with known allergy or hypersensitivity to AG120 or venetoclax.
Doxycycline allergy
Allergy or intolerance to roflumilast
Known allergy to PEGylated products
Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab
History of gastritis or malabsorption syndrome or aspirin intolerance or allergy
Patients with a history of allergy to medications that have a benzamide structure (e.g., metoclopramide, procarbazine, domperidone, cisapride etc.) are not eligible
Bupivacaine or liposomal bupivacaine sensitive or known allergy.
Known allergy to eggs, egg products, aminoglycoside antibiotics (e.g. gentamicin or tobramycin)
Known allergy to anthracyclines.
Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen
History of allergy to merestinib or chemically related compounds
An allergy or intolerance to egg, gluten or milk protein
Subject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.
Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents
Allergy to benzamide or inactive components of entinostat
Known allergy or hypersensitivity to IP
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy or hypersensitivity to intraperitoneal (IP) or any excipient
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy to grapes or grape seed
Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist
Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy or intolerance to lidocaine
Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded
Gadolinium allergy
Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded
Allergy to benzamide or inactive components of entinostat
Known allergy to coenzyme Q10
Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K
Known allergy to doxycycline or tetracycline
Known allergy to ODM-201 or any of the excipients.
History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine
Patients with known allergy to cremophor or polysorbate 80
Known allergy to PIO
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy or hypersensitivity to agents used within the treatment protocol
Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)
Patients who have known allergy to mebendazole
DONOR: Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test products
Patient has a history of allergy or intolerance to flucytosine.
Patients with known carboplatin or cisplatin allergy
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to sulfa or specific allergy to sulfonylurea drugs
Allergy to gadolinium
Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol
Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Allergy to filgrastim, pegfilgrastim, or loratadine
Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Gold allergy
Known history of allergy to Captisol®
Patients with known allergy, intolerance, or resistance (i.e., remission duration less than 6 months or lack of response) to ifosfamide, carboplatin, or etoposide
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Patients with a known allergy to dimethyl sulfoxide (DMSO)
Patients with a known history of allergy to soy products
MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
History of allergy to penicillin or related antibiotic
Patients with an allergy or known hypersensitivity to fish
Known allergy to any of the agents or their ingredients used in this study
Allergy to oseltamivir or excipients
Known allergy to domperidone
Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, cyclosporine, or mycophenolate mofetil.
Patients with latex allergy.
Patients who have an allergy to gold.
Corn allergy
History of allergy to KLH, QS-21, OPT-821, or glucan
History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine, that cannot be controlled using basic angiographic techniques
History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine, that cannot be controlled using basic angiographic techniques
History of photosensitizing disease (porphyria, lupus etc.) or of allergy to methylene blue dye.
Patients are excluded if there is any history of gadolinium allergy.
Patient having known allergy to NSAID or Aspirin
Known allergy to doxorubicin or anthracyclines.
History of allergy or hypersensitivity to the device constituent or Inserter materials.
Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;
History of allergy or hypersensitivity to any of the study drugs.
Patient has a prior allergy or intolerance of ketoconazole
Patient has an allergy or intolerance to sulfites
Patients with known allergy to MB
Known allergy(ies) to any component of CMB305 or LV305.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Known allergy to hyaluronidase
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Patients with prior allergy to daunorubicin and/or cytarabine
Patients who have an allergy/intolerance to sirolimus
DONOR: Known allergy to filgrastim (GCSF)
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to or intolerance of prior doxorubicin-based TACE
Known history of allergy to Captisol®
Soy allergy
History of allergy or untoward reaction to prior vaccination with vaccinia virus
Known history of positive serum human ADA, or known allergy to any component of ADCT-301.
Known allergy(ies) to any component of CMB305 or CPA
Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy
Known allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.
History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Known allergy to both penicillin and sulfa antibiotics
No known allergy to platinum compounds
History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically
Known allergy to latex or gadolinium (Gd).
Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy(ies) to any component of the study agent GLA-SE including egg lecithin
Have a known allergy to tomatoes or have never consumed tomatoes
Known allergy to thalidomide.
Known allergy to ovalbumin or other egg products
Allergy to ganciclovir or acyclovir
Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)
Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
Patient has a history of allergy to red color food dye.
A known allergy to any component of LY2157299.
Known allergy to hyaluronidase
Allergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)
Patients with documented allergy to cephalosporins
Has allergy to enzalutamide
Patient has a known allergy to both penicillin and sulfa
All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine
Patients with known allergy to eggs
Known history of allergy to Captisol
Allergy to soy, egg, or peanut products
Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)
Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine
Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)
Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)
Known allergy to any of the study medications
A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.
Patients who have known allergy to mebendazole or benzimidazole
Allergy or hypersensitivity to agents used within the treatment protocol
Known allergy to any of the compounds under investigation
Have a known allergy to resiquimod or any of the excipients in the study drug
Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy
If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > 99.5 Fahrenheit [F]/37.5 Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy
Known allergy to gadolinium
Known or suspected allergy to pazopanib
18F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intolerance
Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.
History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Known or suspected allergy to ARQ 197
Allergy to benzamide or inactive components of entinostat
Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)
Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.
Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.
Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible
DONOR: Known allergy to G-CSF
Patients will be excluded if they have a known allergy to any of the drugs used in the study
Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
Known allergy to bone cement,
Patients will be excluded if they have a known allergy to any of the drugs used in the study.
Any known allergy to the compounds under investigation
Patients with known allergy or hypersensitivity to IMGN901
Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis
Known allergy to hyaluronidase or any constituents of docetaxel formulation.
Bovine product allergy
Known allergy to any of the study drugs
Prior history of penicillin or streptomycin allergy
Known intolerance or allergy to medications used for sedation (midazolam), analgesia (fentanyl), and local and regional anesthesia (lidocaine, bupivacaine, and ropivacaine)
Patients with a soy allergy will be excluded
History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)
Patient has a history of allergy or hypersensitivity to the study drugs
The subject has a known allergy to tetracycline
Patient has a history of allergy or hypersensitivity to the study drugs
Known allergy to macrolide antibiotics
Known allergy to any of the study agents
Allergy to either of the study medications or 5-fluorouracil
Nut allergy
Patient has a known allergy to bovine or porcine products.
Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.
Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)
Patient who has a history of allergy or hypersensitivity to any of the study drugs
Does the subject have a history of allergy or intolerance to flucytosine?
Known allergy to treatment medication (vemurafenib)
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to study medications
History of significant drug-related allergy (such as anaphylaxis)
Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds
Known allergy to doxycycline or other tetracycline antibiotics
History of allergy to Urelumab (BMS-663513) or related compounds
History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy
Known allergy to any of the study medications
allergy or intolerance to 5-FC
Allergy: known hypersensitivity to other recombinant human antibodies
Known allergy to eggs
Allergy to gadolinium
Known allergy to any of the agents or their ingredients used in this study
Allergy to bupropion
Known allergy to adhesive tape
Known or suspected allergy to pamidronate or related products
Known allergy to EACA
Allergy to allopurinol
known allergy to both penicillin and sulfa drugs
Allergy to egg or egg byproducts
Known history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimus
Allergy to botulinum toxin, and or egg
Fish and/or fish oil allergy or intolerance
Milk allergy excluding lactose intolerance
Allergy or intolerance to bupivacaine or “amide” anesthetics
Known allergy to soy or any soy-based food or supplement
Known allergy to local anesthetics
Known allergy to perampanel
Known allergy to or prior intolerance of aspirin and/or simvastatin
History of an allergy to romiplostim
Allergy treatment with antigen injections
Allergy or adverse reaction to local anesthesia catheter
Known true tape allergy
No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)
Known allergy to stevia
Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone
Allergy treatment with antigens injections
Patients with a known allergy or hypersensitivity to CHG are ineligible
Patients with an allergy to quinolones
Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo
Known allergy to a probiotic preparation
Food allergy to any component of the supplement
History of allergy to investigational agent: ropivacaine or other amino amide analgesics
History of allergy to standard agent: propofol
Allergy to gabapentin
No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms
Antibiotic allergy to study medication
Allergy to bone morphogenetic protein
Allergy to bovine collagen products
Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
Patients with documented allergy to egg products.
Patients with documented allergy to soy products.
Previous intolerance/adverse effect/allergy to any component of the placebo or active agent
Allergy to beef
Participant has a known allergy to melatonin or any ingredients of the study product or placebo
Patients must not have an allergy to latex
Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline
No known allergy to either ACE inhibitors or ?-blockers
Known allergy to phenylephrine
Doxycycline allergy
Allergy to sugar substitute
Allergy to gabapentin
Allergy to either Eucerin or MF
Known allergy or preexisting skin disease which prohibits use of menthol
Patients with a history of allergy or adverse reaction to corticosteroids
Known allergy to a probiotic preparation
Allergy or intolerance to gadolinium
Participants who have a known allergy to contrast media.
Participants who have a known allergy to contrast media
History of allergy to acetic acid
History of allergy to apixaban or Factor Xa inhibitors
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity
Known allergy to electrode adhesives or woven knit compression fabrics
RECIPIENT: Allergy treatment with antigens injections
Known allergy to LCM or LEV
Known history of allergy to any component or other contraindications to any Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.
Individuals with a known allergy to lidocaine are not eligible
History of allergy or intolerance to ISA
History of allergy to eggs, egg products, aminoglycoside antibiotics
Women with an allergy to rapamycin or its derivatives
Have a known allergy or food intolerance to ingredients in study products (black raspberries or other berries)
Documented allergy to apixaban and/or enoxaparin
Allergy to nicotine patch, nicotine lozenge, or varenicline
Patient has allergy to fish or is a vegetarian
Patients who have an allergy to eggs
Known allergy to eggs, egg products
Bovine product allergy.
Subjects with a known allergy to lidocaine
Patients with an allergy to Peridex/chlorhexidine solution
Any serious egg allergy or prior serious adverse reaction to an influenza vaccine
Has a history of significant allergy to calcitriol as determined by the investigator.
Has known allergy to Tc99m sestamibi
Iodide or seafood allergy
Women with a known allergy to proflavine or acriflavine
Known allergy to adhesive tapes or other skin adhesives used in medical care
Allergy to sulfa or sulfa-containing medications
Allergy to sulfa or sulfa-containing medications
History of allergy to iodide drugs or shellfish (iodine allergy)
Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted
Patients with a known allergy to Benadryl
Known allergy to gadolinium or the sedative, propofol, used during MRI
Subjects with established allergy to IV GBCA
Patients with history of allergy to hydrogel dressing or ongoing skin diseases
Has known allergy to Tc 99m sestamibi
Participants who have a known allergy to contrast media
History of prior fluorothymidine allergy or intolerance
Women with a known allergy to proflavine or acriflavine
Patients with allergy to regadenoson
Known allergy or anaphylactic reaction to indocyanine green (ICG).
Severe food or medication allergy
Known allergy to proflavine or acriflavine
History of multiple food and/or drug allergy
No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the dental/medical professional monitoring the study
History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses; allergy to personal care/consumer products or their ingredients
Has a known allergy to dextran or VBD (if intended to be used)
Known allergy to gadolinium.
No allergy to gadolinium
History of any anaphylactic reaction, any severe allergy, or any allergy to folate
Has a known allergy to dextran
Known allergy to FdCyd
Allergy to fluoroquinolones
Allergy to any component of sipuleucel-T
Allergy to Brussels sprouts
Nut or seed allergy
No known allergy to tree nuts
Participant must not have a history of allergy to erlotinib
Known hypersensitivity to 5-fluorouracil/leucovorin
Patients with a known hypersensitivity to the combination/comparator agent
Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin
Patients with known hypersensitivity to any TZD oral agents are not eligible
Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization
Patients with a history of hypersensitivity to nickel
History of hypersensitivity to any of the additives in the alectinib drug formulation
Hypersensitivity to carboplatin or cisplatin
Patients with history of hypersensitivity to liposomal products
Patients with a known hypersensitivity to the combination/comparator agent
Hypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade 3 that is managed, is allowed.
Patients with a known hypersensitivity to carboplatin
Hypersensitivity to:
Known hypersensitivity to afatinib, cisplatin, or pemetrexed
No history of severe hypersensitivity reaction to Cremophor EL
Known hypersensitivity to platinum compounds
Those with porphyria or with known hypersensitivity to porphyrins or porphyrin-like compounds
Documented hypersensitivity reaction to any product with GSE
History of severe hypersensitivity reactions to cisplatin or vinblastine or other products of the same class;
History of hypersensitivity to sertraline
History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction.
Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds
Known hypersensitivity to the metal in the electrodes (stainless steel 304 L) that cannot be medically managed
Part B only: Hypersensitivity to study drugs given in combination with LY3023414
Known hypersensitivity to methotrexate
Known hypersensitivity to bortezomib, ixazomib, dexamethasone, or ONC201
The patient has known hypersensitivity to gelatin or lactose monohydrate
History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics or opioids.
Known hypersensitivity to the device constituent or TARIS Inserter materials.
Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product
Known hypersensitivity/intolerance to capecitabine, infusional 5-flurouracil, or bevacizumab
Subjects who have hypersensitivity to decitabine, CDX-1401, poly-ICLC or nivolumab
Previous hypersensitivity to rapamycin or rapamycin derivatives
Carotid sinus hypersensitivity syndrome.
History of clinical hypersensitivity to the immunotherapy proposed for combination treatment.
A history of sun hypersensitivity or photosensitive dermatitis.
History of hypersensitivity to IP or comparator agents
Has known hypersensitivity to baker's yeast
History of hypersensitivity to thyrotropin alpha (Thyrogen)
Known hypersensitivity to Avidin or AvidinOX (e.g. hen egg)
Patients with known contraindications to radiotherapy including inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., ataxia telangiectasia, Nijmegen breakage syndrome)
History of hypersensitivity to the combination or comparator agent (if applicable)
Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
History of hypersensitivity to the combination or comparator agent
Documented hypersensitivity to bumetanide or sulfonamides
Has hypersensitivity to nivolumab or any other drug used in this protocol
Known or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.
Patients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivity
Known hypersensitivity or intolerance to any of the agents under investigation
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor®, or history of hypersensitivity type reaction to polysorbate 80 or other components of the formulation of Oraxol
Patients with inherited syndromes associated with hypersensitivity to ionizing radiation, specifically patients with known history of ataxia-telengiectasia, Nijmegen breakage syndrome
Known hypersensitivity to deferasirox
Known hypersensitivity to S-1 or its metabolites (eg, 5-FU);
History of hypersensitivity to any of the kinase inhibitors included in this study
History of hypersensitivity to the combination or comparator agent
History of hypersensitivity to hydrogel.
History of hypersensitivity to tremelimumab or the combination of MEDI4736 + tremelimumab
Hypersensitivity to simvastatin or ezetimibe.
Patients with known hypersensitivity to taxanes or platinums are to be excluded
A history of hypersensitivity to selumetinib, or any excipient agents (e.g. Captisol or TPGS- a water soluble form of Vitamin E)
Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5–fluorouracil
History of allergy or untoward reaction to yeast-based products (any hypersensitivity to yeast-based products will be excluded)
Patients with a known hypersensitivity to interferon-alpha
Known hypersensitivity to 5-FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.)
Subjects with history of hypersensitivity to azoles
Patients with known hypersensitivity to pegfilgrastim and filgrastim
Anergic, defined by the inability to make a Delayed-type Hypersensitivity (DTH) to at least one of the following: candida, mumps, tetanus or trichophyton (based upon availability)
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Hypersensitivity of TZD
Known hypersensitivity or other serious adverse reaction to any azole antifungal therapy or to any other ingredient of the study medication used.
Hypersensitivity to mithramycin
History of hypersensitivity to vemurafenib
Patients with history of hypersensitivity to conductive hydrogel are not eligible
Patients who are (MVF-HER-2[266-296] and MVF-HER-2 [597-626]) immediate hypersensitivity skin test positive
Known severe hypersensitivity to trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur)
Have a history of hypersensitivity to dacarbazine (DTIC)
History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;
Hypersensitivity to fluphenazine or other phenothiazines
Hypersensitivity to any reagents used in the study.
Known hypersensitivity to enzalutamide
Hypersensitivity to acetazolamide or sulfonamides
Has known serious hypersensitivity reactions to peg-interferon alfa-2b or interferon alfa-2b
Known hypersensitivity or intolerance to any of the agents under investigation
Known hypersensitivity to arsenic trioxide
History of hypersensitivity to the combination or comparator agent (If applicable)
Known hypersensitivity to Cremophor®-based agents
No known hypersensitivity to Escherichia (E.) coli-derived products
Patients with a prior hypersensitivity reaction to sargramostim
The subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC)
Patients with a known hypersensitivity to gemtuzumab ozogamicin or its parts: recombinant humanized anti-CD33 monoclonal (hP67.6) antibody, calicheamicin derivatives or other ingredients
TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide
Patients with known contraindications to radiotherapy, including inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., ataxia-telangiectasia, Nijmegen breakage syndrome)
Hypersensitivity to mithramycin
Known hypersensitivity to inactive ingredient of TPI 287
History of hypersensitivity to dacarbazine
Hypersensitivity to trial medications (everolimus)
Hypersensitivity to any of the study medications
Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible
Serious hypersensitivity reaction to egg products
A history of ataxia telangiectasia or other documented history of radiation hypersensitivity
Patients who have hypersensitivity to sitagliptin
Patients with previous hypersensitivity reaction to camptothecins are excluded
Documented hypersensitivity to clobetasol
Must not have known hypersensitivity to 4-aminoquinoline compound
Patients with a known hypersensitivity to BKM120, RAD001 (including other rapalogs) or their excipient
Hypersensitivity to interferon alfa
Suspected hypersensitivity to IFN alfa2b
Patient must not be known to have hypersensitivity to TAK-700, to TAK-700 metabolites, to bicalutamide, or to LHRH agonist
Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).
History of intolerance or hypersensitivity to study drug
Subject has a history of hypersensitivity to porcine derived gelatin or collagen.
Subject has a history of hypersensitivity to microbial Transglutaminase.
Known history of immunogenicity or hypersensitivity to a CD25 antibody.
Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib.
Hypersensitivity or prior treatment with obinutuzumab
Known hypersensitivity to the study treatment or any of its ingredients.
Known history of immunogenicity or hypersensitivity to a CD19 antibody.
Intolerance or hypersensitivity to octreotide
Known hypersensitivity to 5-fluorouracil/leucovorin
Prior treatment with or hypersensitivity to study drug or related compounds
Known hypersensitivity to bicalutamide.
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Patients with known hypersensitivity to any TZD oral agents are not eligible
History of hypersensitivity to LCI699 or to drugs of similar chemical classes.
Immediate or delayed hypersensitivity to digoxin or trametinib
Patients who have exhibited hypersensitivity reactions to regorafenib and/or a structural compound, biological agent, or formulation (e.g., sorafenib)
History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation
History of hypersensitivity to anakinra.
History of hypersensitivity to everolimus.
History of hypersensitivity to castor oil
Immediate or delayed hypersensitivity to digoxin
History of hypersensitivity to TPIV200
Hypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteins
Known hypersensitivity to enzalutamide or related compounds
Subject has a known hypersensitivity to platinum compounds.
Known hypersensitivity to everolimus or bendamustine
Documented hypersensitivity to any of the drugs used in the protocol
Subject has a known hypersensitivity to platinum compounds.
Known intolerance or hypersensitivity to vitamin E, everolimus or to rapamycin derivatives
Known hypersensitivity to 5-fluorouracil/leucovorin
Known hypersensitivity to capecitabine
Known hypersensitivity to cytarabine, daunorubicin or liposomal products
Known hypersensitivity to any immunomodulatory drugs (IMiDs), including Grade 4 rash
Known hypersensitivity or intolerance to dexamethasone
Patients must not have known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Steven-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other products component
Known hypersensitivity to both allopurinol and rasburicase
History of hypersensitivity to any compound in the tetracycline antibiotics group
Steroids for the treatment of hypersensitivity or transfusion reactions.
Prior history of infusion reactions or hypersensitivity to any of the study drugs
Known hypersensitivity reaction to mushroom products
Patients with a known hypersensitivity to tacrolimus
Patients with known hypersensitivity to Escherichia coli (E.coli)-derived proteins, filgrastim, or any component of filgrastim are not eligible
History of hypersensitivity to ipilimumab
Known anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogs
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Patients with known hypersensitivity to rapamycins
No known hypersensitivity to 4-aminoquinoline compound
Patients with hypersensitivity to any tetracyclines
Known hypersensitivity reaction or idiosyncrasy to erlotinib
No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol
Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
A history of ataxia telangiectasia or other documented history of radiation hypersensitivity
Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin, 2 phenoxyethanol, formaldehyde, aluminum hydroxide, yeast
Known hypersensitivity to fluoropyrimidines or cisplatin.
History of hypersensitivity to sirolimus
History of hypersensitivity to vorinostat
History of hypersensitivity to hydroxychloroquine
Prior carboplatin or cisplatin hypersensitivity reaction
Any history of adverse reaction or hypersensitivity to LDAC
Known history of hypersensitivity to aromatase-inhibitor drugs
Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.
Prior treatment with or have known hypersensitivity to AL3818.
b. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine.
c. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine.
History of hypersensitivity to tremelimumab
Has known hypersensitivity to baker's yeast
History of Grade ? 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen
Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP8273, erlotinib or gefitinib.
Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class
Known history of ? Grade 3 hypersensitivity to a therapeutic antibody.
History of hypersensitivity to the combination or comparator agent
Known hypersensitivity to filgrastim or to Escherichia coli (E. coli) derived proteins
Known hypersensitivity to any constituent of the study medication.
History of hypersensitivity to 4-aminoquinoline compound
Known hypersensitivity to 5-azacytidine\r\n* Prior treatment with 5-azacytidine is allowed
Known hypersensitivity to dacarbazine (DTIC).
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Known hypersensitivity to any inactive ingredient of TPI 287
Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules
Known hypersensitivity to lithium or tretinoin
Has a known hypersensitivity to baker's yeast or has an active yeast infection;
Patients with hypersensitivity to amiodarone or NAC
Hypersensitivity to obinutuzumab
Patients with known hypersensitivity or intolerance to melphalan
Subjects with porphyria’s or known hypersensitivity to porphyrins
There are no known contra-indications to any of the planned agents used in this protocol; etoposide may be substituted by etoposide phosphate (Etopophos) if the patient has a history of hypersensitivity reaction to etoposide
Known hypersensitivity to rosuvastatin
Hypersensitivity to cytarabine, daunorubicin or liposomal products
Known intolerance of or hypersensitivity to fosbretabulin
Known hypersensitivity to filgrastim, plerixafor, or Escherichia (E.) coli derived products
Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4 infusion related reactions with anti-EGFR mABs
Have known hypersensitivity to platinum (Pt) compounds
History of hypersensitivity to hydrogel
Hypersensitivity to recombinant human IL-2
Known hypersensitivity to Tween-80, or human immunoglobulin
Known hypersensitivity to study-assigned chemotherapy
Hypersensitivity to 4-aminoquinoline compounds, including hydroxychloroquine sulfate, chloroquine phosphate and amodiaquine
History of hypersensitivity to amikacin or other aminoglycosides
Subjects with known hypersensitivity to peptide drugs, including LHRH agonists.
History of hypersensitivity to taxanes or drug formulations containing Cremophor®.
Known hypersensitivity to varenicline
Prior history of a hypersensitivity reaction to PLD, doxorubicin, bortezomib, carfilzomib, or liposomal drug formulations other than PLD
Suspected hypersensitivity to interferon alpha
Hypersensitivity to trial medications
Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.
Hypersensitivity to cytarabine, daunorubicin or liposomal products
History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,
Have a known hypersensitivity to olanzapine or to phenothiazines
History of hypersensitivity to other psychostimulants
Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible
Known hypersensitivity (example, anaphylactic and anaphylactoid reactions) to any particular combination drug will result in a participant being ineligible for inclusion in that particular cohort.
Known hypersensitivity to cold
History hypersensitivity to opioids.
History of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonists
PATIENTS: History of hypersensitivity to haloperidol or chlorpromazine
Patients with hypersensitivity to ropivacaine/amide-type anesthetics
Patient has a known hypersensitivity to the administration of any prescribed oral or intravenous study medication or metabolite, including but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, or systemic infection
Hypersensitivity to pregabalin
History of hypersensitivity to pregabalin or gabapentin
History of hypersensitivity or severe intolerance to azoles
Hypersensitivity to ginseng
Patients with known hypersensitivity to octreotide or somatostatin
Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible
Patients with a history of echinocandin or azole hypersensitivity are not eligible
History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone
Patients with hypersensitivity to any tetracycline
History of hypersensitivity to haloperidol or benzodiazepine
Patients with hypersensitivity to tetracyclines
Minocycline trial only: patients with hypersensitivity to any tetracyclines
No history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings)
Patients with known hypersensitivity to sildenafil or other ingredients of sildenafil
Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents
History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
Previous documented history of moderate to severe hypersensitivity to Gd contrast agents
Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.
Previous medical history of, or suspected hypersensitivity to, the PEG based bowel cleansing preparation and/or bowel cleansing formulations' ingredients.
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of known latex hypersensitivity
Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of known latex hypersensitivity
History of hypersensitivity or idiosyncratic reactions to azoles
Known hypersensitivity to NAC
Patients who have hypersensitivity to sitagliptin
Known hypersensitivity to cyclophosphamide or any of its metabolites
History of hypersensitivity reaction to Xolair or any ingredient of Xolair
History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study
History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients
Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir) formulations
Subjects with a known hypersensitivity to calcitriol
The patient has a known hypersensitivity to Lymphazurin or Lymphoseek
Individuals with history of cutaneous photosensitivity, porphyria, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis
HEALTHY VOLUNTEER: Known hypersensitivity to UCAs
History of hypersensitivity to nickel
History of cutaneous photosensitivity, porphyria, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis
Hypersensitivity to iodide products
Hypersensitivity to dextran and/or modified form thereof
Previous hypersensitivity reaction to LAR octreotide
Hypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoids
Patients with history of hypersensitivity reaction to any component of 89Zr-DFO-MSTP2109A, including DFO
The subject has a known hypersensitivity to Isosulfan Blue Dye.
Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
EXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
Patients with known hypersensitivity including anaphylaxis to trabectedin
Known hypersensitivity or intolerance to itraconazole or similar class agents.
Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim
Hypersensitivity to Caphosol ingredients
The patient received omacetaxine or has a history of hypersensitivity.
Patients with a history of hypersensitivity to nickel.
Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule.
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor
Known history of immunogenicity or hypersensitivity to a CD19 antibody.
Known or suspected allergy or hypersensitivity to the study drug
Known prior or suspected hypersensitivity to investigational products
Patients with known hypersensitivity to perflutren
Known hypersensitivity to study drug and/or drug class
Has a known hypersensitivity to any of the study therapy products
Known hypersensitivity to any study drug used in this trial
Known hypersensitivity to any study drug
Known or suspected hypersensitivity to ruxolitinib.
Known hypersensitivity to any study drug
Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial
Known hypersensitivity to any study drug
Known hypersensitivity to acyclovir or similar anti-viral drug
Has a known hypersensitivity to any of the study therapy products
Known hypersensitivity to trial drug
Known hypersensitivity to acyclovir or similar anti-viral drug
Known prior or suspected hypersensitivity to investigational products.
Hypersensitivity to acyclovir or similar anti-viral drug
Known hypersensitivity to any study drug
Patients with known or suspected hypersensitivity to perflutren
History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason
Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity)
Known hypersensitivity to any component of perflutren lipid (Definity)
Hypersensitivity to perflutren
Known hypersensitivity to perflutren (if the patient has been exposed to perflutren in the past and had an allergic reaction)
Women with known cardiac shunt, pulmonary hypertension or hypersensitivity to perflutren agent
Patients with known or suspected hypersensitivity to perflutren
Patients with any known hypersensitivity to perflutren agent
Patients with known hypersensitivity to perflutren
Patients with known hypersensitivity to perflutren
Known or suspected: hypersensitivity to perflutren, blood, blood products or albumin
Known or suspected: hypersensitivity to a prior perflutren protein-type A microspheres (OPTISON) administration
Have known sensitivity to any component of bevacizumab
Have known sensitivity to any component of paclitaxel
History of known radiation sensitivity syndrome
Subject has a known sensitivity to any of the components of the investigational product AGS62P1:
Known sensitivity to any of the products or components to be administered during dosing.
Pts with known sensitivity to any immunomodulatory drugs (IMiDs)
Known sensitivity to any of the products or components to be administered during dosing.
Known sensitivity or allergy to murine products or any component of RO6870810, venetoclax, or rituximab.
Known sensitivity to immunoglobulins or any of the components to be administered during dosing.
Has had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.
Subject with known sensitivity to starch or starch-derived materials;
Known sensitivity to conductive hydrogels
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan
Known sensitivity to any of the ingredients of the investigational product enfortumab vedotin (ASG-22CE)
Patient has known sensitivity to any of the products to be administered during dosing
Known contraindications to radiotherapy including but not limited to radiation sensitivity syndromes such as xeroderma pigmentosum and ataxia telangiectasia mutated
Known allergic reactions, irritations or sensitivity to the active ingredients or other components of SOR007;
Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing
Known sensitivity to any of the study medication components
Known previous history of sensitivity to talimogene laherparepvec or any of its components to be administered during dosing (e.g. sorbitol, myo-inositol)
Subject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products
Has known sensitivity to any of the ingredients of:
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Patients with a known sensitivity to any of the products to be administered during treatment
Patients with preexisting known or suspected radiation sensitivity syndromes will be excluded
Known sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded
Known sensitivity to any of the products to be administered during dosing
Patients with a known history of a severe allergy or sensitivity to wheat gluten
Known or suspected drug sensitivity to cytarabine or the investigational agent ficlatuzumab
Patients with known sensitivity to any immunomodulatory drugs (IMiDs)
History of sensitivity to, or history of conditions that are known to cause sensitivity to, radiation therapy
Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products
Known sensitivity to any study medication
Known sensitivity to E. coli derived products.
Have a known sensitivity to any of the components of Andes-1537
Patients with known sensitivity to alcohol.
217 Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.
Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
Known sensitivity to any of the products to be administered during the study (e.g., calcium, or vitamin D)
Has known sensitivity to retinoic acid derivatives
Subject has known sensitivity to any of the components of the investigational product AGS67E:
Sensitivity score =< 3
Patient must not have known sensitivity to TRC102 or any formulation excipients
Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.
Known sensitivity to any of the ingredients of the investigational product AGS15E
Known sensitivity to E. coli derived products or known sensitivity to any of the products to be administered during dosing
Has known sensitivity to capecitabine or metabolites
Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
Patients with a known sensitivity to any of the products to be administered during treatment and assessments.
Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials
Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
Patients with known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Patients with known sensitivity to retinoic acid derivatives
Known sensitivity to any of the components of the investigational product AGS67E:
Prior sensitivity to plerixafor
Patients have known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known sensitivity to ferumoxytol
Sensitivity to conductive hydrogels
Known sensitivity to any of the products that will be administered during the study
Patient must not have known sensitivity to terameprocol or any formulation excipients
History of sensitivity to any component of SD-101
Patients with known sensitivity or allergy to any components of AMP-224
Known sensitivity to TAS-102, CPT-11, Bevacizumab, or their components
Known sensitivity to any of the ingredients of the investigational product AGS-16C3F
Known sensitivity or contraindication to any component of study treatment
Has a known sensitivity to 5-FU
Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or IMC-18F1, or other agents that specifically target VEGF
Subject has known sensitivity or allergy to heparin
Known sensitivity to bendamustine
Known sensitivity to mannitol
Subject has known sensitivity to any of the products to be administered during dosing
Women with sensitivity to silver
Known sensitivity to omalizumab
Known sensitivity to conductive hydrogels.
Known sensitivity or allergy to fish or fish oil
Patients with known sensitivity or allergy to porcine materials
Sensitivity to silver
Sensitivity to amide-type local anesthetics
Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Subjects with a known sensitivity to any of the Investigational Product components
Have sensitivity or allergy to fish and/or shellfish
Have sensitivity or allergy to soy and/or soybeans
Known sensitivity to any of the components of the Levulan Kerastick for topical solution
Known sensitivity or allergy to fish
Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D)
Known sensitivity or allergy to turmeric spices or curry
Subjects with known sensitivity to any device or products required for the RALP surgery; and
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products
Demonstrate hyperinsulinemia with a quantitative insulin sensitivity check index (QUICK I) value =< 0.357
Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).
Known sensitivity to fluorescent light
Known sensitivity to 18F FSPG or components of the preparation
Known sensitivity to fluorescent light
Known sensitivity to any of the study medication components or the chemotherapy regimen
A known history of contrast sensitivity
Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
Known Stage IV ovarian cancer with brain metastases 14. Received an investigational agent in another clinical trial within 30 days prior to surgery 15. Known sensitivity to fluorescent light
Known or suspected sensitivity to diagnostic imaging contrast agents.
Known or suspected sensitivity to indocyanine green (ICG).
Known sensitivity to fluorescent light
Subject has known sensitivity to any of the products or components to be administered during dosing.
History of hypersensitivity reactions to murine protein-containing products
EXCLUSION - TREATMENT: History of hypersensitivity reactions to murine protein-containing products
TREATMENT EXCLUSION: History of hypersensitivity reactions to murine protein-containing products
History of hypersensitivity reactions to murine protein-containing products
EXCLUSION - TREATMENT: History of hypersensitivity reactions to murine protein-containing products
AUTOLOGOUS APHERESIS: History of hypersensitivity reactions to murine protein-containing products
TREATMENT WITH SJCAR19: History of hypersensitivity reactions to murine protein-containing products
A known hypersensitivity to any of the test materials or related compounds including murine and bovine products;
Patients with known allergy to bovine or murine products
No history of hypersensitivity reactions to murine protein-containing products
ELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Must not have a history of hypersensitivity to murine protein-containing products
AT THE TIME OF INFUSION: History of hypersensitivity reactions to murine protein-containing products
No known hypersensitivity to murine products
History of hypersensitivity reactions to murine protein-containing products
History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation
History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
History of hypersensitivity to cetuximab, murine products, or any component of the formulation
History of hypersensitivity reactions to murine protein-containing products
History of hypersensitivity reactions to murine protein-containing products
Patients with known allergy to bovine or murine products.
No history of hypersensitivity to murine protein containing products
History of hypersensitivity reactions to murine protein-containing products
History of hypersensitivity reactions to murine protein-containing products
Known sensitivity or allergy to murine products.
History of hypersensitivity reactions to murine protein-containing products
No known hypersensitivity to murine products
Known sensitivity or allergy to murine products.
History of hypersensitivity to bevacizumab or murine products, temsirolimus or its metabolites, or any component of the formulation
History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
History of hypersensitivity reactions to murine protein-containing products
Has no known allergy to murine products or positive HAMA
History of hypersensitivity to doxil, doxorubicin, hydrochloride (HCL), temsirolimus or its metabolites (including sirolimus), polysorbate 80, bevacizumab or murine products
Patients with known systemic allergy to bovine or murine products
History of hypersensitivity reactions to murine protein-containing products
